 announced the expansion of its drug metabolism services to include drug-transporter interactions with eight human transporters. Under this expansion, Covance now offers assessment of drug-transporter interactions involving major human transporters key to drug disposition in a stably transfected, cell-based format regarded as a superior model for reliable, reproducible results. 
 
“For more than 30 years, Covance has helped our clients achieve a detailed understanding of the disposition of their drug candidates,” said Jon Denissen, PhD, Vice President of Global Drug Metabolism. “The addition of drug-transporter interactions to our service offering enables our clients to define the importance of transporters in their drug discovery and development programs, select the best drug candidates, and meet the latest expectations of regulatory agencies.”

Eight cell lines stably expressing human transporters in the Covance drug-transporter interactions service include P-glycoprotein (P-gp/MDR1), breast cancer resistant protein (BCRP), organic cation transporters 1& 2 (OCT1 & OCT2), organic anion transporter 3 (OAT3), organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 & OATP1B3), and multidrug resistance-associated protein 2 (MRP2).  
 
Through its wholly-owned laboratories located in the United States, Europe, and Asia, Covance offers clients access to comprehensive and integrated portfolios of drug metabolism services, including preclinical PK, 

 radiolabeled ADME, metabolite identification, and PK/TK analysis.